Advertisement
AXON vs TECH
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Bio-Techne (TECH) Stock Comparison
Key Takeaways
- AXON is a high-growth public-safety technology company whose shares fell sharply in recent weeks after a quarterly revenue and earnings miss, while TECH trades near its agreed acquisition price following a deal to be bought by Merck KGaA.
- AXON retains a powerful recurring-revenue engine — software and services grew roughly 43% and annual recurring revenue (ARR) rose about 40% — even as delayed federal drone deployments and rising memory costs pressured near-term momentum.
- TECH is effectively "deal-anchored": its pending all-cash acquisition at $73 per share caps upside while limiting downside, leaving limited independent near-term catalysts.
- The two names present a clear trade-off in market positioning: AXON offers growth and volatility, while TECH offers stability with minimal standalone upside.
- Tickeron AI Verdict: Axon Enterprise (AXON) is the favored ticker, based on its stronger underlying recurring-revenue trajectory and longer-term catalysts despite recent price weakness.
- For deeper context on each name, explore AXON Major News and AXON Today's Price Move, as well as TECH Major News and TECH Today's Price Move.
- To see which AI strategies are currently favored by the market, explore Trending AI Robots.
Introduction
This stock comparison examines two very different publicly traded companies: AXON, better known as Axon Enterprise, and TECH, or Bio-Techne Corporation. Axon operates in public-safety hardware and software, while Bio-Techne is a life-sciences reagents and diagnostics supplier. Growth-oriented investors may weigh Axon's high-growth, high-volatility profile against the stability Bio-Techne offers as a company under an agreed acquisition. Traders focused on relative performance and market positioning will find the contrast instructive, since the two names respond to entirely different drivers — government procurement cycles versus biotech research funding and M&A (mergers and acquisitions) dynamics.
AXON Overview and Recent Performance
Axon Enterprise (AXON) develops conducted-energy weapons (Tasers), body cameras, cloud-based evidence-management software, and increasingly drone and counter-drone systems. Recent market activity has been volatile. In its latest quarterly report, revenue rose about 28% year over year to roughly $909 million, but the figure missed consensus expectations, and adjusted earnings per share (EPS) also came in below estimates. Management lowered its full-year revenue outlook, citing roughly $130 million in delayed federal drone (Dedrone) deployments tied to procurement timing.
The selloff that followed erased a significant share of the stock's value in a single session, extending a longer 2026 decline and pushing shares near 52-week lows. Yet the underlying business showed resilience: software and services revenue accelerated to roughly 43% growth, ARR grew about 40%, and future contracted bookings reached approximately $15.8 billion. Sentiment has been shaped both by margin pressure from memory costs and by Axon's announcement of a $1.2 billion investment raising its stake in drone maker Skydio to 37%, signaling a deeper strategic commitment to autonomous aerial systems.
TECH Overview and Recent Performance
Bio-Techne Corporation (TECH) is a global life-sciences company supplying specialized proteins, antibodies, reagents, analytical instruments, and diagnostics across its Protein Sciences and Diagnostics and Spatial Biology segments. Its recent stock behavior has been far less dramatic than Axon's, largely because of a definitive agreement announced in late June for Bio-Techne to be acquired by Merck KGaA for $73 per share in cash, representing an enterprise value of roughly $11.3 billion.
Because of that pending transaction, TECH shares have traded in a narrow band near the deal price. The underlying operating results have been modest: fiscal fourth-quarter net sales rose about 1% to roughly $321 million, with full-year revenue essentially flat at about $1.2 billion. Organic growth has been constrained by softness in emerging biotech spending, though large-pharma demand and spatial-biology products have shown strength. With investor conference calls suspended amid the acquisition, the stock's near-term path is driven primarily by deal progress rather than standalone fundamentals.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a much larger library of hundreds of automated strategies that collectively trade thousands of different tickers. Rather than listing every bot, this section highlights only those whose performance and configuration are best suited to current market conditions. Each bot operates with its own trading style, strategy, timeframe, risk profile, and set of tickers, so the roster adapts as market regimes shift. Whether you are evaluating names like AXON and TECH or scanning the broader market, reviewing the Trending AI Robots can provide a data-driven starting point for identifying which strategies are currently resonating.
Head-to-Head Comparison
The two companies occupy unrelated sectors, which makes their relative performance a study in contrasting risk profiles rather than direct competition. AXON is exposed to government and law-enforcement budgets, carries elevated valuation multiples relative to earnings, and is reinvesting heavily into drones and AI-driven software. Its growth drivers are strong but lumpy, as the delayed federal deployments demonstrated. TECH, by contrast, is tied to biopharma and academic research funding cycles and now carries the distinct feature of being acquisition-bound.
From a momentum standpoint, AXON has recently underperformed amid guidance cuts and margin compression, while TECH has been comparatively stable, anchored near its $73 deal price. The trade-off is clear: Axon offers a broader range of possible outcomes with meaningful long-term upside tied to its recurring-software business, whereas Bio-Techne offers limited volatility but equally limited standalone return potential, with the primary remaining variable being deal completion.
Tickeron AI Verdict
Weighing trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would currently lean toward AXON. The rationale is that Bio-Techne's price is effectively tethered to its acquisition agreement, which suppresses both downside risk and independent upside, whereas Axon retains a durable, high-growth recurring-revenue engine and a multiyear pipeline of catalysts spanning software subscriptions, AI products, and drone expansion. While Axon's near-term price trend has been negative and volatility elevated, the AI framework tends to place greater weight on underlying business momentum and forward-looking catalysts than on a single guidance revision. This is a probabilistic assessment of relative positioning rather than a definitive forecast, and either outcome remains possible depending on deal timing, procurement execution, and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and TECH is a Hold.
AXON in upward trend: price may jump up because it broke its lower Bollinger Band on November 06, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 30 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
TECH's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TECH turned positive on November 09, 2026. Looking at past instances where TECH's MACD turned positive, the stock continued to rise in 27 of 40 cases over the following month. The odds of a continued upward trend are 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on TECH as a result. In 57 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
Following a +0.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where TECH advanced for three days, in 190 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 94 of 231 cases where TECH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 41%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TECH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
TECH broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. TECH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.414) is normal, around the industry mean (3.498). TECH has a moderately high P/E Ratio (62.205) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (2.110) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (9.346) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TECH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON | TECH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 83 | 100 | |
SMR RATING 1..100 | 81 | 74 | |
PRICE GROWTH RATING 1..100 | 66 | 19 | |
P/E GROWTH RATING 1..100 | 80 | 89 | |
SEASONALITY SCORE 1..100 | 30 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (90) in the Biotechnology industry is in the same range as TECH (94). This means that AXON’s stock grew similarly to TECH’s over the last 12 months.
AXON's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as TECH (100). This means that AXON’s stock grew similarly to TECH’s over the last 12 months.
TECH's SMR Rating (74) in the Biotechnology industry is in the same range as AXON (81). This means that TECH’s stock grew similarly to AXON’s over the last 12 months.
TECH's Price Growth Rating (19) in the Biotechnology industry is somewhat better than the same rating for AXON (66). This means that TECH’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's P/E Growth Rating (80) in the Biotechnology industry is in the same range as TECH (89). This means that AXON’s stock grew similarly to TECH’s over the last 12 months.
| AXON | TECH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | N/A |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 66% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 55% |
| Advances ODDS (%) | 16 days ago 74% | 3 days ago 66% |
| Declines ODDS (%) | 2 days ago 70% | 20 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 41% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while TECH’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- TECH’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while TECH’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 5 bearish.
- TECH’s TA Score: 4 bullish, 3 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -27.37% price change this week, while TECH (@Biotechnology) price change was +0.22% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +5.77%. For the same industry, the average monthly price growth was -0.40%, and the average quarterly price growth was -12.12%.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.28%. For the same industry, the average monthly price growth was -2.47%, and the average quarterly price growth was -12.98%.
Reported Earning Dates
AXON is expected to report earnings on Mar 02, 2027.
TECH is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Aerospace & Defense (+5.77% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+5.28% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | -0.21% | ||
| TECH - AXON | 61% Loosely correlated | -0.01% | ||
| VCYT - AXON | 58% Loosely correlated | -7.18% | ||
| BEAM - AXON | 57% Loosely correlated | -6.92% | ||
| SEER - AXON | 56% Loosely correlated | -4.17% | ||
| ADPT - AXON | 56% Loosely correlated | -2.97% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FLEU | 35.05 | 0.02 | +0.06% |
| Franklin FTSE Eurozone ETF (FLEU) | |||
| IEFA | 97.16 | -0.52 | -0.53% |
| iShares Core MSCI EAFE ETF (IEFA) | |||
| DJP | 48.16 | -0.28 | -0.59% |
| iPath Bloomberg Commodity Index Total Return ETN (DJP) | |||
| VBCH | 72.57 | -0.47 | -0.64% |
| Vanguard Target Maturity 2034 Corporate Bond ETF (VBCH) | |||
| XTWY | 34.70 | -0.56 | -1.59% |
| BondBloxx Bloomberg Twenty Year Target Duration US Treasury ETF (XTWY) | |||